Modulation of immune responses strategies for optimising vaccines

Expert Opinion on Biological Therapy

Volumn 4, Issue 5, 2004, Pages 627-630

  Dumont, Alain R ^a,b   Kalfayan, Lina H ^a,b   Sékaly, Rafick P ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Adjuvants; Dendritic cells; Memory; T lymphocytes; Vaccine

Indexed keywords

ADJUVANT; EPITOPE; VACCINE;

ADJUVANT THERAPY; ADOPTIVE IMMUNOTHERAPY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG RESEARCH; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; NONHUMAN; REVIEW; VACCINATION;

EID: 2442705258     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.5.627     Document Type: Review

References (24)

1. JANEWAY CA JR, MEDZHITOV R: Innate immune recognition. Annu. Rev. Immunol. (2002) 20(1):197-216. In this review article, the authors provide an extensive description of the specific receptors (namely TLRs) and mechanisms involved in the innate immune response.
2. CARL VS, BROWN-STEINKE K, NICKLIN MJH, SMITH MF JR: Toll-like receptor 2 and 4 (TLR2 and TLR4) agonists differentially regulate secretory interleukin-1 receptor antagonist gene expression in macrophages. J. Biol. Chem. (2002) 277(20):17448-17456.
3. SMITH MF JR, MITCHELL A, LI G et al.: Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-{kappa}B activation and chemokine expression by epithelial cells. J. Biol. Chem. (2003) 278(35):32552-32560.
4. DARVILLE T, O'NEILL JM, ANDREWS CWJR et al.: Toll-like receptor-2, but not toll-like receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection. J. Immunol. (2003) 171(11):6187-6197.
5. LEE J, CHUANG TH, REDECKE V et al.: Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc. Natl. Acad. Sci. USA (2003) 100(11):6646-6651.
6. HEMMI H, KAISHO T, TAKEUCHI O et al.: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. (2002) 3(2):196-200.
7. ROTHENFUSSER S, HORNUNG V, AYYOUB M et al.: CpG-A and CpG-B oligonucleotides differentially enhance human peptide-specific primary and memory CD8+ T-cell responses in vitro. Blood (2003) 103(6):2162-2169.
8. SEAMAN MS, PEYERL FW, JACKSON SS et al.: Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence the efficiency of secondary expansion in vivo. J. Virol. (2004) 78(1):206-215. This article describes how the timely administration of a plasmid DNA encoding a cytokine (namely IL-12) leads to the generation of different subsets of T lymphocytes, and the involvement of central versus effector memory subsets of the latter in the generation of a potent immune response in the context of a gp120 HIV DNA vaccination strategy.
9. KIM JJ, YANG JS, DENTCHEV T, DANG K, WEINER DB: Chemokine gene adjuvants can modulate immune responses induced by DNA vaccines. J. Interferon Cytokine Res. (2000) 20(5):487-498.
10. DISIS ML, SCHOLLER N, DAHLIN A et al.: Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity. Mol. Cancer Ther. (2003) 2(10):995-1002.
11. BUKCZYNSKI J, WEN T, ELLEFSEN K, GAULDIE J, WATTS TH: Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses. Proc. Natl. Acad. Sci. USA (2004) 101(5):1291-1296. The costimulatory ligand 4-1BBL is described as an adjuvant in the induction of antiviral memory CD8 T cells with its potential use in combination with prime/boost vaccine strategies in the context of viral infections.
12. AGADJANYAN MG, CHATTERGOON MA, HOLTERMAN MJ et al.: Costimulatory molecule immune enhancement in a plasmid vaccine model is regulated in part through the Ig constant-like domain of CD80/86. J. Immunol. (2003) 171(8):4311-4319. A series of chimaeric CD80 and CD86 costimulatory molecule constructs as well as respective deletion mutants were used as adjuvants to determine their immune activating potential in two DNA immunisation models. This study demonstrates that the lack of an Ig constant-like region in the CD80 molecule is critically important in immune activation.
13. YUKI Y, KIYONO H: New generation of mucosal adjuvants for the induction of protective immunity. Rev. Med. Virol. (2003) 13(5):293-310.
14. NOAD R, ROY P: Virus-like particles as immunogens. Trends Microbiol. (2003) 11(9):438-444.
15. JALAVA K, EKO FO, RIEDMANN E, LUBITZ W: Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery. Expert Pev. Vaccines (2003) 2(1):45-51.
16. ROEDERER M, KOUP RA: Optimized determination of T cell epitope responses. J. Immunol. Methods (2003) 274(1-2):221-228.
17. DE GROOT AS, SBAI H, AUBIN CS, MCMURRY J, MARTIN W: Immuno-informatics: mining genomes for vaccine components. Immunol. Cell Biol. (2002) 80(3):255-269.
18. MARTIN W, SBAI H, DE GROOT AS: Bioinformatics tools for identifying class I-restricted epitopes. Methods (2003) 29(3):289-298.
19. TAKAHASHI H, NAKAGAWA Y, PENDLETON CD et al.: Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant. Science (1992) 255(5042):333-336.
20. BERZOFSKY JA, AHLERS JD, BELYAKOV IM: Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. (2001) 1(3):209-219.
21. SLANSKY JE, RATTIS FM, BOYD LF et al.: Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity (2000) 13(4):529-538. This article discusses the involvement of altered peptide ligands in the generation of more potent immune responses in the context of tumour vaccines, thus stressing the importance of the latter in the careful design of succesful vaccination strategies.
22. BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392:245-252.
23. MARTIN-FONTECHA A, SEBASTIANI S, HOPKEN UE et al.: Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J. Exp. Med (2003) 198(4):615-621.
24. KAECH SM, WHERRY EJ, AHMED R: Effector and memory T-cell differentiation: implications for vaccine development. Nat. Rev. Immunol. (2002) 2(4):251-262. This review article highlights the importance of commitment signals leading to effector or memory T cell generation and the implications in vaccine strategy optimisation.